每經(jing)AI快訊，2024年2月2日(ri)，深(shen)交所(suo)(suo)(suo)向山東(dong)未(wei)(wei)(wei)名(ming)生物醫(yi)(yi)藥股(gu)(gu)(gu)份有限(xian)(xian)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)及(ji)相(xiang)關(guan)(guan)(guan)(guan)當事(shi)(shi)(shi)(shi)人(ren)發出監(jian)(jian)管函：根據中國(guo)(guo)證券監(jian)(jian)督管理(li)(li)委員(yuan)會(hui)(hui)山東(dong)監(jian)(jian)管局下發的(de)《關(guan)(guan)(guan)(guan)于(yu)對(dui)山東(dong)未(wei)(wei)(wei)名(ming)生物醫(yi)(yi)藥股(gu)(gu)(gu)份有限(xian)(xian)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)及(ji)相(xiang)關(guan)(guan)(guan)(guan)人(ren)員(yuan)采(cai)取出具警(jing)示(shi)函措(cuo)施的(de)決定(ding)(ding)(ding)》查明的(de)事(shi)(shi)(shi)(shi)實(shi)，你(ni)(ni)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)存在以下違規(gui)(gui)(gui)(gui)行(xing)為(wei)：一(yi)、未(wei)(wei)(wei)按(an)規(gui)(gui)(gui)(gui)定(ding)(ding)(ding)披(pi)(pi)露(lu)關(guan)(guan)(guan)(guan)聯(lian)方(fang)資金往(wang)來2022年，你(ni)(ni)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)子公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)未(wei)(wei)(wei)名(ming)生物醫(yi)(yi)藥有限(xian)(xian)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)通過(guo)供(gong)應商與你(ni)(ni)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)原實(shi)際(ji)控(kong)制人(ren)潘愛(ai)華(hua)(hua)控(kong)制的(de)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)發生資金往(wang)來，構(gou)成關(guan)(guan)(guan)(guan)聯(lian)交易(yi)，你(ni)(ni)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)未(wei)(wei)(wei)按(an)規(gui)(gui)(gui)(gui)定(ding)(ding)(ding)履(lv)(lv)(lv)行(xing)相(xiang)應的(de)審(shen)議程(cheng)序(xu)和信(xin)息(xi)(xi)披(pi)(pi)露(lu)義(yi)(yi)(yi)務(wu)。二、未(wei)(wei)(wei)按(an)規(gui)(gui)(gui)(gui)定(ding)(ding)(ding)披(pi)(pi)露(lu)對(dui)外(wai)擔保2018年12月，你(ni)(ni)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)原實(shi)際(ji)控(kong)制人(ren)、時(shi)任(ren)(ren)(ren)董(dong)(dong)(dong)(dong)(dong)(dong)事(shi)(shi)(shi)(shi)長潘愛(ai)華(hua)(hua)以你(ni)(ni)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)名(ming)義(yi)(yi)(yi)為(wei)原控(kong)股(gu)(gu)(gu)股(gu)(gu)(gu)東(dong)北京北大(da)未(wei)(wei)(wei)名(ming)生物工程(cheng)集團有限(xian)(xian)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)與第(di)三方(fang)的(de)《借(jie)款合(he)同》提供(gong)擔保。你(ni)(ni)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)未(wei)(wei)(wei)就(jiu)該事(shi)(shi)(shi)(shi)項履(lv)(lv)(lv)行(xing)董(dong)(dong)(dong)(dong)(dong)(dong)事(shi)(shi)(shi)(shi)會(hui)(hui)及(ji)股(gu)(gu)(gu)東(dong)大(da)會(hui)(hui)審(shen)議程(cheng)序(xu)，未(wei)(wei)(wei)在臨時(shi)公(gong)(gong)(gong)(gong)(gong)告及(ji)定(ding)(ding)(ding)期報告中履(lv)(lv)(lv)行(xing)信(xin)息(xi)(xi)披(pi)(pi)露(lu)義(yi)(yi)(yi)務(wu)。你(ni)(ni)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)的(de)相(xiang)關(guan)(guan)(guan)(guan)行(xing)為(wei)違反(fan)(fan)了(le)本(ben)所(suo)(suo)(suo)《股(gu)(gu)(gu)票(piao)上(shang)(shang)市(shi)(shi)規(gui)(gui)(gui)(gui)則(ze)》第(di)1.4條(tiao)(tiao)(tiao)、第(di)2.1條(tiao)(tiao)(tiao)、第(di)9.11條(tiao)(tiao)(tiao)，《股(gu)(gu)(gu)票(piao)上(shang)(shang)市(shi)(shi)規(gui)(gui)(gui)(gui)則(ze)》第(di)1.4條(tiao)(tiao)(tiao)、第(di)2.1.1條(tiao)(tiao)(tiao)、第(di)6.3.6條(tiao)(tiao)(tiao)的(de)規(gui)(gui)(gui)(gui)定(ding)(ding)(ding)。你(ni)(ni)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)時(shi)任(ren)(ren)(ren)董(dong)(dong)(dong)(dong)(dong)(dong)事(shi)(shi)(shi)(shi)長潘愛(ai)華(hua)(hua)，時(shi)任(ren)(ren)(ren)總(zong)(zong)經理(li)(li)SHUHONGHAN，時(shi)任(ren)(ren)(ren)董(dong)(dong)(dong)(dong)(dong)(dong)事(shi)(shi)(shi)(shi)長、總(zong)(zong)經理(li)(li)、聯(lian)席總(zong)(zong)經理(li)(li)岳家霖(lin)，時(shi)任(ren)(ren)(ren)財務(wu)總(zong)(zong)監(jian)(jian)劉陽軍，時(shi)任(ren)(ren)(ren)董(dong)(dong)(dong)(dong)(dong)(dong)事(shi)(shi)(shi)(shi)會(hui)(hui)秘書趙(zhao)輝未(wei)(wei)(wei)能(neng)恪盡職守、履(lv)(lv)(lv)行(xing)誠(cheng)實(shi)勤(qin)勉義(yi)(yi)(yi)務(wu)，違反(fan)(fan)了(le)本(ben)所(suo)(suo)(suo)《股(gu)(gu)(gu)票(piao)上(shang)(shang)市(shi)(shi)規(gui)(gui)(gui)(gui)則(ze)》第(di)1.4條(tiao)(tiao)(tiao)、第(di)2.1.2條(tiao)(tiao)(tiao)的(de)規(gui)(gui)(gui)(gui)定(ding)(ding)(ding)，對(dui)相(xiang)關(guan)(guan)(guan)(guan)違規(gui)(gui)(gui)(gui)行(xing)為(wei)一(yi)負有重要責(ze)任(ren)(ren)(ren)。時(shi)任(ren)(ren)(ren)董(dong)(dong)(dong)(dong)(dong)(dong)事(shi)(shi)(shi)(shi)長潘愛(ai)華(hua)(hua)，時(shi)任(ren)(ren)(ren)總(zong)(zong)經理(li)(li)定(ding)(ding)(ding)丁學國(guo)(guo)，時(shi)任(ren)(ren)(ren)聯(lian)席總(zong)(zong)經理(li)(li)徐若然，時(shi)任(ren)(ren)(ren)董(dong)(dong)(dong)(dong)(dong)(dong)事(shi)(shi)(shi)(shi)會(hui)(hui)秘書王立君未(wei)(wei)(wei)能(neng)恪盡職守、履(lv)(lv)(lv)行(xing)誠(cheng)實(shi)勤(qin)勉義(yi)(yi)(yi)務(wu)，違反(fan)(fan)了(le)本(ben)所(suo)(suo)(suo)《股(gu)(gu)(gu)票(piao)上(shang)(shang)市(shi)(shi)規(gui)(gui)(gui)(gui)則(ze)》第(di)1.4條(tiao)(tiao)(tiao)、第(di)2.2條(tiao)(tiao)(tiao)的(de)規(gui)(gui)(gui)(gui)定(ding)(ding)(ding)，對(dui)相(xiang)關(guan)(guan)(guan)(guan)違規(gui)(gui)(gui)(gui)行(xing)為(wei)二負有重要責(ze)任(ren)(ren)(ren)。本(ben)所(suo)(suo)(suo)希望你(ni)(ni)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)及(ji)全體董(dong)(dong)(dong)(dong)(dong)(dong)事(shi)(shi)(shi)(shi)、監(jian)(jian)事(shi)(shi)(shi)(shi)、高(gao)級管理(li)(li)人(ren)員(yuan)認(ren)真吸取教(jiao)訓(xun)，并提醒(xing)你(ni)(ni)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)及(ji)全體董(dong)(dong)(dong)(dong)(dong)(dong)事(shi)(shi)(shi)(shi)、監(jian)(jian)事(shi)(shi)(shi)(shi)、高(gao)級管理(li)(li)人(ren)員(yuan)嚴(yan)格遵守《證券法(fa)(fa)》《公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)法(fa)(fa)》等(deng)法(fa)(fa)律法(fa)(fa)規(gui)(gui)(gui)(gui)，以及(ji)本(ben)所(suo)(suo)(suo)《股(gu)(gu)(gu)票(piao)上(shang)(shang)市(shi)(shi)規(gui)(gui)(gui)(gui)則(ze)》及(ji)相(xiang)關(guan)(guan)(guan)(guan)規(gui)(gui)(gui)(gui)定(ding)(ding)(ding)，真實(shi)、準確、完整(zheng)、及(ji)時(shi)、公(gong)(gong)(gong)(gong)(gong)平地履(lv)(lv)(lv)行(xing)信(xin)息(xi)(xi)披(pi)(pi)露(lu)義(yi)(yi)(yi)務(wu)，杜絕此類事(shi)(shi)(shi)(shi)件發生。

2023年1至6月(yue)份，未名醫藥的(de)營業收入構成為：制(zhi)藥業務(wu)分部占比(bi)100.0%。

未名醫藥的總經理、董事長均是岳家霖，男，55歲，學歷背(bei)景(jing)為(wei)本科(ke)。

截至(zhi)發(fa)稿，未名(ming)醫(yi)藥市值(zhi)為67億元(yuan)。

道達號(hao)（daoda1997）“個股趨勢”提醒：
1. 未名醫藥近30日內北向資金持股量增加73.35萬股，占流通股比例增加0.19%；
2. 近30日內無(wu)機構對(dui)未名醫藥進行調研。

每經頭(tou)條(tiao)（nbdtoutiao）——

(記者 蔡鼎)

免責(ze)聲明：本(ben)文內容與數(shu)據僅(jin)供參考，不構成投資建(jian)議，使用(yong)前請核實。據此操(cao)作，風險(xian)自(zi)擔。